The ocean contains diverse carbohydrates that could serve as valuable resources for drug development. Algae, marine animals and microorganisms produce polysaccharides and related molecules with structures that are uncommon on land, including distinctive sulfate patterns, sugar linkages and branched architectures. These features can support antiviral, anticoagulant, immunomodulatory and antitumor activity, while also providing useful properties for drug delivery, wound healing and tissue engineering.
A review in Glycoscience & Therapy brought together findings on the sources, structures and biological activities of these marine carbohydrates and examined how some have progressed into medicines. Marine carbohydrates are often studied in terms of individual biological activities, but their clinical development requires a broader understanding of how structure, production, quality control, and mechanisms of action are connected. By examining approved drugs alongside clinical-stage candidates, the review provides a clearer picture of the progress achieved and the challenges that remain.
The authors of the review followed a clinical timeline that begins with cytarabine, a marine-inspired leukemia drug approved in the United States in 1969, and included later carbohydrate-based products derived from alginate, carrageenan and other marine materials. They also surveyed the candidates currently being evaluated in clinical trials for viral infections, cancer, metabolic disorders, tissue repair, cystic fibrosis and neurological disease.
Further, the review focused on what is required to turn a complex natural carbohydrate into a reproducible medicine. Molecular weight, sulfation pattern and monosaccharide composition can all affect activity, but they may also vary with species, season, extraction and processing.
“Our review highlights several priorities for future development: establishing reliable production methods through cultivation, fermentation, or enzymatic processing; improving structural and activity-based quality control; validating molecular targets and mechanisms; and conducting more rigorous pharmacokinetic and safety studies,” says senior and co-corresponding author Guangli Yu. “Progress in these areas will require close collaboration among researchers in glycoscience, analytical chemistry, synthetic biology, materials science, and clinical research.”
###
Contact author details:
Guangli Yu, Key Laboratory of Marine Drugs, Ministry of Education, Shandong Key Laboratory of Glycoscience and Glycotherapeutics, School of Medicine and Pharmacy, Ocean University of China, Qingdao, China. glyu@ouc.edu.cn
Chao Cai, Key Laboratory of Marine Drugs, Ministry of Education, Shandong Key Laboratory of Glycoscience and Glycotherapeutics, School of Medicine and Pharmacy, Ocean University of China, Qingdao, China. caic@ouc.edu.cn
The publisher KeAi was established by Elsevier and China Science Publishing & Media Ltd to unfold quality research globally. In 2013, our focus shifted to open access publishing. We now proudly publish more than 300 world-class, open access, English language journals, spanning all scientific disciplines. Many of these are titles we publish in partnership with prestigious societies and academic institutions, such as the National Natural Science Foundation of China (NSFC).
Glycoscience & Therapy
Literature review
Not applicable
Development of marine organisms derived carbohydrate-based drugs: From bioactivity to clinical translation